Kalydeco was initially approved in 2012 to treat patients aged over six with a single mutation of the cystic fibrosis transmembrane regulator (CFTR) gene - known as G551D - which affects around ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

This means that the lumacaftor-Kalydeco combination could have an even greater commercial potential than Kalydeco's current licensed use, although analysts doubt it can show the same level of ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

Wall Street ended last week in positive territory, but it hasn’t been a smooth journey for stocks this year. Markets turned ...

These are the generic equivalent of 'Kalydeco' oral granules, 25 mg, 50 mg, and 75 mg, of Vertex Pharmaceuticals Incorporated. "Lupin is the exclusive first-to-file for this product and may be ...